Sep 22, 2022 Avenue Therapeutics Announces Reverse Stock Split and Provides Regulatory Update for IV Tramadol Including Receipt of Type A Meeting Minutes from the FDA
Nov 29, 2021 Avenue Therapeutics Announces FDA Advisory Committee Meeting to Review IV Tramadol NDA Tentatively Scheduled for February 15, 2022
Nov 17, 2021 Avenue Therapeutics Announces Exercise and Closing of Underwriter’s Over-Allotment Option
Oct 25, 2021 Avenue Therapeutics Receives Interim Response to its Formal Dispute Resolution Request from U.S. Food and Drug Administration Office of New Drugs
